• Alterity Therapeutics presented new Phase 2 analyses of ATH434 in multiple system atrophy at the 2026 MDS Congress.
• Adjusted results showed the 50 mg dose slowed functional decline versus placebo over one year, strengthening the disease-modifying signal.
• Baseline CSF neurofilament light chain emerged as a predictor of progression, supporting its use to sharpen outcomes in a Phase 3 trial.
• Imaging analyses were broadly consistent with ATH434’s iron-chaperone approach, despite the study missing its primary imaging endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-031946), on October 05, 2026, and is solely responsible for the information contained therein.